In bladder cancer, data from the CheckMate-275 and IMvigor210 trials demonstrated that patients with ARID1A mutations and high CXCL13 expression had favorable outcomes following ICI treatment (33). This evidence concerns the gene ARID1A and urinary bladder cancer.